TNF-alpha antagonist therapy improves insulin sensitivity: In non-diabetic ankylosing spondylitis patients

Clinical and Experimental Rheumatology

Volumn 30, Issue 6, 2012, Pages 850-855

  Miranda Filloy, J A ^a   Llorca, J ^b   Carnero Lopez B ^c   Gonzalez Juanatey C ^a   Blanco, R ^d   Gonzalez Gay M A ^d  

^a HOSPITAL XERAL CALDE   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c HOSPITAL EL BIERZO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Ankylosing spondylitis; Anti TNF antibody infliximab; Atherosclerosis; Inflammation; Insulin resistance; Insulin sensitivity

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD GLUCOSE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872733932     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. PETERS MJ, VAN DER HORST-BRUINSMA IE, DIJKMANS BA, NURMOHAMED MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 585-92.
2. PETERS MJ, VISMAN I, NIELEN MM et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010; 69: 579-81.
3. GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MIRANDA-FILLOY JA et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009; 88: 358-65.
4. PETERS MJ, VAN EIJK IC, SMULDERS YM et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 2010; 37: 161-6.
5. BODNÁR N, KEREKES G, SERES I et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 2011; 38: 723-9.
6. DESSEIN PH, JOFFE BI, STANWIX AE Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol 2003; 30: 1403-5.
7. SATTAR N, MCCAREY DW, CAPELL H, MCINNES IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
8. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
9. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
10. SARI I, OKAN T, AKAR S et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford) 2006; 45: 283-6.
11. VAN EIJK IC, PETERS MJ, SERNÉ EH et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 2009; 68: 362-6.
12. D'ANGELO S, PALAZZI C, CANTINI F et al. Etanercept in spondyloarthopathies. Part II: Safety and pharmacoeconomic issues. Clin Exp Rheumatol 2011; 29: 865-70.
13. PALAZZI C, D'ANGELO S, CANTINI F et al. Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
14. HELDMANN F, BRANDT J, VAN DER HORSTBRUINSMA IE et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
15. KIORTSIS DN, MAVRIDIS AK, VASAKOS S, NIKAS SN, DROSOS AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
16. VAN DER LINDEN S, VALKENBURG HA, CATS A Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
17. VIS M, NURMOHAMED MT, WOLBINK G et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 252-5.
18. GONZALEZ-GAY MA, DE MATIAS JM, GONZALEZ-JUANATEY C et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 83-6.
19. BONORA E, KIECHL S, WILLEIT J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-9.
20. KATZ A, NAMBI SS, MATHER K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
21. GORDILLO-MOSCOSO A, VALADEZ-CASTILLO JF, MANDEVILLE PB, HERNANDEZ-SIERRA JF. Comparison of equivalence and determination of diagnostic utility of minmod and clamp methods for insulin resistance in diabetes free subjects: a meta-analysis. Endocrine 2004; 25: 259-63.
22. DESSEIN PH, JOFFE BI, STANWIX AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4: R12.
23. SARI I, DEMIR T, KOZACI LD et al. Body composition, insulin, and leptin levels in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 1427-32.
24. HALLGREN R, BERNE C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983; 213: 351-5.
25. SVENSON KL, POLLARE T, LITHELL H, HALLGREN R. Impaired glucose handling in active rheumatoid arthritis: relationship to peripheral insulin resistance. Metabolism 1988; 37: 125-30.
26. PAOLISSO G, VALENTINI G, GIUGLIANO D et al. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism 1991; 40: 902-7.
27. DESSEIN PH, JOFFE BI, STANWIX A, BOTHA AS, MOOMAL Z The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J Rheumatol 2002; 29: 462-6.
28. FUKUZAWA M, SATOH J, QIANG X et al. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Diabetes Res Clin Pract 1999; 43: 147-54.
29. HOTAMISLIGIL GS, PERALDI P, BUDAVARI A, ELLIS R, WHITE MF, SPIEGELMAN BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 27: 665-8.